PCV risk groups: patient group direction template
Patient group direction (PGD) template to support the provision of PCV13 vaccine to individuals with underlying medical conditions.
Applies to England
Documents
Details
This PGD template supports the provision of pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) (PCV13) to individuals with underlying medical conditions.
The PCV Risk Groups PGD v05.00 is valid from 1 March 2022 to 28 February 2024. The expiry date of this PGD is now extended to 28 February 2025, pending an update to Chapter 25 of the Green Book.
Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement see Human Medicines Regulations 2012. Practitioners should follow local policy/procedures to access authorised PGD documents.
This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics.
Updates to this page
Last updated 30 January 2024 + show all updates
-
Added notice of extension.
-
Added v05.00 – see page 2 for change history.
-
Updated with V04.00 document.
-
Added version V03.00 - routine review of PGD prior to expiry.
-
Version 2. Updated PGD dose section in line with revised pneumococcal Green Book chapter and refined inclusion criteria.
-
First published.